Department of Gastroenterological Surgery, Gastroenterological Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan.
Department of Hepato-Biliary-Pancreatic Medicine, Gastroenterological Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Int J Clin Oncol. 2021 Nov;26(11):2029-2036. doi: 10.1007/s10147-021-01990-0. Epub 2021 Jul 28.
We assessed the technical and oncological safety of self-expandable metallic stent (SEMS) insertion followed by laparoscopic colorectal surgery as a bridge to surgery (BTS) for obstructive colorectal cancer (CRC).
A retrospective, single-center study analyzed the short- and long-term outcomes of SEMS insertion followed by laparoscopic colorectal surgery in patients with stage II/III/IV obstructive CRC from 2012 to 2020 at Cancer Institute Hospital.
In 66 patients, including 28 stage IV patients, the clinical success rates of SEMS insertion were 97%. In laparoscopic surgery, primary anastomosis was performed in 61 patients (92%), and open conversion was required in 2 patients (3%). Postoperative complications were seen in 9 patients (13%); however, there was no anastomotic leakage or mortality. Curative resection was achieved in all 38 stage II/III patients and 15 of 28 (54%) stage IV patients. Stage IV patients had a longer operation time and greater blood loss than stage II/III patients; however, the open conversion and postoperative complication rates were similar between the groups. In stage II/III patients, 3-year disease-free survival and 3-year overall survival [OS] were 87.1 and 89.5%, respectively. The median OS of stage IV patients was 34.9 months, and stage IV patients who underwent R0 resection showed a significantly better OS (P = 0.0011) than those with R2 resection.
SEMS insertion followed by laparoscopic surgery is a feasible treatment strategy that achieves a high-primary anastomosis rate without severe postoperative complication in not only stage II/III but also stage IV obstructive CRC patients.
我们评估了自膨式金属支架(SEMS)置入后行腹腔镜结直肠手术作为桥接治疗(BTS)在梗阻性结直肠癌(CRC)中的技术和肿瘤安全性。
回顾性单中心研究分析了 2012 年至 2020 年期间癌症研究所医院收治的 II/III/IV 期梗阻性 CRC 患者接受 SEMS 置入后行腹腔镜结直肠手术的短期和长期结局。
在 66 例患者中,包括 28 例 IV 期患者,SEMS 置入的临床成功率为 97%。在腹腔镜手术中,61 例(92%)患者行一期吻合,2 例(3%)患者需中转开腹。9 例(13%)患者术后出现并发症;但无吻合口漏或死亡。所有 38 例 II/III 期患者和 28 例中的 15 例(54%)IV 期患者均达到根治性切除。IV 期患者的手术时间和出血量均长于 II/III 期患者;但两组的中转开腹率和术后并发症发生率相似。在 II/III 期患者中,3 年无病生存率和 3 年总生存率(OS)分别为 87.1%和 89.5%。IV 期患者的中位 OS 为 34.9 个月,行 RO 切除的 IV 期患者的 OS 明显优于行 R2 切除者(P=0.0011)。
SEMS 置入后行腹腔镜手术不仅在 II/III 期,而且在 IV 期梗阻性 CRC 患者中也是一种可行的治疗策略,可实现高一期吻合率,且无严重术后并发症。